Combining emerging agents in advanced breast cancer

Oncologist

Volumn 16, Issue 6, 2011, Pages 760-771

  Luu, Thehang ^a   Chung, Cathie ^b   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Angeles Clinic and Research Institute   (United States)

Author keywords

Combination therapy; Metastatic breast cancer; Monoclonal antibodies; Small molecule inhibitors; Targeted therapy

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IMATINIB; IXABEPILONE; LAPATINIB; METHOTREXATE; NAVELBINE; NERATINIB; OLAPARIB; PACLITAXEL; PERTUZUMAB; PLACEBO; SORAFENIB; SUNITINIB; THIOTEPA; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; LOADING DRUG DOSE; METASTASIS POTENTIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION;

EID: 79959584093     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0345     Document Type: Article

References (75)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Chia SK, Speers CH, D'yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979.
3. Horner MJ, Ries LAG, Krapcho M et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute. Available at http://www.cancer.org/acs/groups/content/@nho/documents/document/f861009final90809pdf.pdf, accessed March 24, 2011.
4. Barrios CH, Sampaio C, Vinholes J et al. What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol 2009;20: 1157-1162
5. Guarneri V, Conte P. Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy. The Oncologist 2009;14:645-656.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer - V.I. 2010. Available at http://www. nccn.org, accessed March 24, 2011.
7. Cavallo J. Can You Afford Cancer? Cure 2006. Available at http://www.curetoday.com/index.cfm/fuseaction/article.show/id/2/article_id/365, accessed March 24, 2011.
8. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009;31:1619-1640.
9. Fojo T, Menefee M. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 2007;18(suppl 5):v3-v8.
10. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-292.
11. Ferlini C, Raspaglio G, Cicchillitti L et al. Looking at drug resistance mechanisms for microtubule interacting drugs: Does TUBB3 work? Curr Cancer Drug Targets 2007;7:704-712.
12. Cicchillitti L, Penci R, Di Michele M et al. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 2008;7:2070-2079.
13. Metzger-Filho O, Moulin C, de Azambuja E et al. Larotaxel: Broadening the road with new taxanes. Expert Opin Investig Drugs 2009;18:1183-1189.
14. Morris PG, Fornier MN. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther 2009;9:175-185.
15. Lee FY, Smykla R, Johnston K et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63: 201-212.
16. Jimeno A. Eribulin: Rediscovering tubulin as an anticancer target. Clin Cancer Res 2009;15:3903-3905.
17. Thomas ES, Gomez HL, Li RK. et al. Ixabepilone plus capecitabine for met-astatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-5217.
18. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25: 3407-3414.
19. Twelves C, Loesch D, Blum JL et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an an-thracycline and a taxane [abstract CRA1004]. J Clin Oncol 2010;28(18 suppl):958s.
20. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004;9:606-616.
21. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
22. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001;344:783-792.
23. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
24. Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-2792.
25. Valero V, Forbes J, Pegram MD et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 2011;29:149-156.
26. Seidman AD, Conlin AK, Bach A et al. Phase II study of weekly nanopar-ticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC). J Clin Oncol 2008;26(suppl 15):52s.
27. Moulder S, Li H, Wang Met-aletal/et-al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group trial. Breast Cancer Res Treat 2010;119:663-671.
28. Tolaney SM, Najita J, Chen W et al. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Res 2009; 69:Abstract 3137.
29. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
30. ® (lapatinib) tablets [full prescribing information]. Research Triangle Park, NC: GlaxoSmithKline, 2010.
31. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-2704.
32. Krop IE, Burris HA, Rugo H et al. Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1). J Clin Oncol 2009;27(suppl 15):1003.
33. Vogel CL, Burris HA, Limentani S et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2 + metastatic breast cancer (MBC): Final results. J Clin Oncol 2009;27(suppl 15):1017.
34. ClinicalTrials.gov. An Open-Label Study of Trastuzumab-MCC-DM1 (T-DM1) vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA). Available at http://clinicaltrials.gov/show/NCT00829166, accessed March 24, 2011.
35. Gianni L, Lladó A, Bianchi G et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:1131-1137.
36. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144.
37. Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8:215.
38. Petrelli F, Cabiddu M, Cazzaniga ME et al. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. The Oncologist 2008; 13:373-381.
39. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008;26(suppl 15):43s.
40. Baselga J, Gomez P, Awada A et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (BALI-1). Ann Oncol 2010;21(suppl 8):2740.
41. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
42. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastu-zumab-treated breast cancer cells. Cancer Res 2006;66:1630-1639.
43. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapa-tinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-1130.
44. Blackwell KL, Burstein HJ, Sledge GW, et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on tras-tuzumab therapy. Presented at the San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 61.
45. Baselga J, Bradbury I, Eidtmann H, et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neo-adjuvant study of lapatinib, trastuzumab, and their combination plus pacli-taxel in women with HER2-positive primary breast cancer [abstract 291]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-12, 2010.
46. Tsou HR, Overbeek-Klumpers EG, Hallett WA et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 2005;48:1107-1131.
47. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus pac-litaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
48. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26(suppl 15):43s.
49. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(suppl 15): 1005.
50. O'Shaughnessy J, Miles D, Gray RJ et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010;28(suppl 15):1005.
51. Brufsky A, Rivera RR, Hurvitz SA et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2010;28(suppl 15):1021.
52. Gradishar W, Kaklamani V, Prasad-Sahoo T et al. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer (BC) [abstract nr 44]. Cancer Res 2009;69:44.
53. Baselga J, Segalla JGM, Roché H et al. SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients with locally advanced (adv) or metastatic (met) breast cancer (BC). Eur J Cancer Suppl 2009;7:3-4.
54. Burstein HJ, Elias AD, Rugo HS. et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-1816.
55. Liljegren A, Bergh J, Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast 2009;18: 259-262.
56. Bergh J, Greil R, Voytko N et al. Sunitinib (SU) in combination with do-cetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010;28(18 suppl):LBA1010.
57. Crown J, Dieras V, Staroslawska E et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010;28(18 suppl):LBA1011.
58. Chew HK, Barlow WE, Albain K et al. A phase II study of imatinib mesy-late and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin Breast Cancer 2008;8:511-515.
59. Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: From bench to bedside. Ann Oncol 2011;22:268-279.
60. Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer [abstract CRA501]. J Clin Oncol 2009;27(18 suppl):7s.
61. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gem-citabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial [abstract 3]. J Clin Oncol 2009;27(18 suppl):793s.
62. Gelmon KA, Hirte HW, Robidoux A et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract 3002]. J Clin Oncol 2010;28(15 suppl):233s.
63. Rodriguez AA, Makris A, Wu MF et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010;123:189-196.
64. Lu CH, Wyszomierski SL, Tseng LM et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007;13:5883-5888.
65. Cardoso F, Gianni L, Jerusalem G et al. Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab. Eur J Cancer Suppl 2009;7:261.
66. Gui CY, Ngo L, Xu WS et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004;101:1241-1246.
67. Finnin MS, Donigian JR, Cohen A et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999;401:188-193.
68. de Ruijter AJ, van Gennip AH, Caron HN et al. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003;370:737-749.
69. Luu TH, Morgan RJ, Leong L et al. A phase II trial of vorinostat (suberoyl-anilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 2008;14:7138-7142.
70. Chen S, Ye J, Kijima I et al. The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. Proc Natl Acad Sci U S A 2010;107:11032-11037.
71. Crevel G, Bates H, Huikeshoven H et al. The Drosophila Dpit47 protein is a nuclear Hsp90 co-chaperone that interacts with DNA polymerase alpha. J Cell Sci 2001;114:2015-2025.
72. Lee FY, Castaneda S, Inigo I et al. Ixabepilone (BMS-247550) plus tras-tuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 2005;23(16 suppl):19s.
73. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
74. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.
75. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002;49:211-216.